AutoGenomics was founded in 1999 as Neuron Technologies and applied to go public in 2008. AutoGenomics, Inc. company developed a genetic testing system called INFINITI that scans DNA samples for genetic disorders, infectious diseases, cancer, and pharmacogenetics (a patient's genetic likeliness to have an adverse reaction to a drug). AutoGenomics found about 25 uses for the INFINITI, but only four have been approved by the FDA for diagnostic use -- testing for sensitivity to the popular blood thinner warfarin, screening for the risk of developing cystic fibrosis or cervical cancer (for women with HPV), and testing for a gene that blocks common drugs from working.

Surface Logix creates new drugs by tweaking the pharmacokinetic and pharmacodynamic properties of existing drugs and new compounds. Its Pharmacomer Technology improves a drug's solubility and permeability in the body and reduce side effects. It has a pipeline of pre-clinical and clinical candidates in development for treatment of metabolic diseases and hypertension. Its drug candidate SLx-4090 is in clinical trials to test its ability to lower blood lipid levels, reduce triglyceride uptake, and block absorption of other fats. Its SLx-2101 candidate is being investigated for treatment of hypertension and Raynaud's Syndrome.

Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

Medicis Pharmaceutical Corporation was founded in 1987 and is headquartered in Scottsdale, Arizona. Medicis Pharmaceutical Corporation operates as a specialty pharmaceutical company in the United States and Canada. It develops and markets products for the treatment of dermatological, aesthetic, and podiatric conditions. The company's products address various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. Its products include DYNACIN for the treatment of acne and acne-related dermatological conditions; PLEXION, a cleanser product; SOLODYN for the treatment of inflammatory lesions; TRIAZ, a benzoyl peroxide pad for the topical treatment of acne vulgaris; and ZIANA, a gel used on the skin for treatment of acne in patients 12 and older.Medicis Pharmaceutical also offers LOPROX, a shampoo; PERLANE and RESTYLANE for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds; and VANOS, a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. In addition, Medicis Pharmaceutical provides non-dermatological products, including AMMONUL for treating hepatic encephalopathies; and BUPHENYL for the treatment of urea cycle disorder. The company sells its products primarily to wholesale pharmaceutical distributors and retail pharmacy chains. It has a joint development agreement with IMPAX Laboratories, Inc. to develop of five strategic dermatology product opportunities, including an advanced-form SOLODYN product; a strategic alliance with AAIPharma, Inc. for the development, commercialization, and license of a key dermatologic product, SOLODYN; and a strategic collaboration with Hyperion Therapeutics, Inc. for the research and development of a compound referred to as GT4P for the treatment of urea cycle disorder and hepatic encephalopathies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.